Get the latest tech news
First randomized trial of Ozempic for alcoholism shows big drops in drinking
Dr. Christian Hendershot from UNC announced preliminary study results of a 48-person randomized trial that compared semaglutide (Ozempic / Wegovy) to placebo for reduction of drinking in non-treatment seeking participants. The initial findings, presented today at the annual CPDD Conference in Montreal, indicate greater reductions in drinking for semaglutide vs. placebo groups for several drinking outcomes. For some drinking outcomes, reductions in consumption for the semaglutide group were significantly larger than the placebo group. This is a big result and is the first completed RCT examining effects of semaglutide on alcohol outcomes . Early estimates of the size of the effects suggest substantially stronger effects than are typically seen for currently approved medications for alcohol use disorder.
Dr. Christian Hendershot from UNC announced preliminary study results of a 48-person randomized trial that compared semaglutide (Ozempic / Wegovy) to placebo for reduction of drinking in non-treatment seeking participants. Our focus at CASPR is always on scale and strategy: which policies or medications give us the best chance of achieving a society-wide reduction of addiction and its cascade of downstream harms? There have been incremental improvements in existing treatment tools over the past 20 years but we’re still not anywhere close to solving the opioid crisis or reducing alcohol, cocaine, or methamphetamine use.
Or read this on Hacker News
